Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025

Data from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSamantha I. LiangParker Institute for Cancer ImmunotherapyZQZoe QuandtUniversity of California, San FranciscoSWSara WienkeGuardant (United States)

Discussion

Loading...

Member takes

Implication

Observational analysis linked tumor fraction decreases to improved overall and progression-free survival in cancer patients, indicating potential for ctDNA monitoring.

Key Points

  • Patients with a decrease in tumor fraction while on immune checkpoint inhibitors had longer progression-free survival.
  • A ≥80% decrease in tumor fraction indicated significantly better outcomes, with a hazard ratio of 0.24 for progression-free survival.
  • Analysis involved 1,997 plasma samples from 627 patients, revealing early molecular responses ahead of clinical progression.
  • Monitoring changes in tumor fraction provides earlier response data, enhancing treatment decision-making in cancer care.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94feddcehttps://doi.org/10.1158/2767-9764.c.7990832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  2. 2Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  3. 3Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  4. 4Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  5. 5Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025